All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
A phase 3 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Overview
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06956170 by GlaxoSmithKline, with 21 participants enrolled, started 2022-02-10 and due to reach its primary completion in 2024-05-27. Interventions recorded: Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Belantamab mafodotin, Pomalidomide, Bortezomib, GSK.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
- TrialJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
- TrialA Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.
- TrialStudy of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple
Shares Belantamab mafodotin, GSK, Multiple myeloma.
- TrialSub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Shares Belantamab mafodotin, GSK, Dexamethasone, Multiple myeloma.